Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC, page-100

Hi Green;

Any situation where tumor cells are dying efti activates APC’s through its ligand MHCII. It’s working, let’s go big.

By any situation are you saying that origin of the cancer doesn't matter? What we have been calling cancer is really immunologic failure?
Activation of APCs with efti in the presence of cancer antigens allows APCs to recruit and reprogram CD8 t cells to seek out cancer cells.
Still need to remove cancer's cloaking mechanism, e.g. their immune checkpoints so the CD8 t cells can hone in and do their job.

This is very interesting and explains why efti combined with checkpoint inhibitors shows benefits across the cancer spectrum.
We need first line studies and early treatment before the opportunity for immune control is lost to fibrosis and tumor burden.